The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | The changing landscape of BTK-targeted therapies for B-cell lymphomas and CLL
In this video, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, briefly comments on the evolving landscape of BTK-targeted therapies for B-cell malignancies. BTK inhibitors have been a valuable treatment option in several indications, and the ongoing development of BTK degraders will likely provide another therapeutic approach for patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
BTK inhibitors have been very valuable drugs in the treatment of B-cell malignancies. Currently, the standard of care in CLL, mantle cell lymphoma. And also, nevertheless, some patients progress during the use of non-covalent BTK inhibitors and newer agents, such as pirtobrutinib, have been associated with also improving the outcome in these patients. Interestingly, there are several BTK degraders that have been in development and the initial data is showing that the current study also seems to provide encouraging results in B-cell malignancies...
BTK inhibitors have been very valuable drugs in the treatment of B-cell malignancies. Currently, the standard of care in CLL, mantle cell lymphoma. And also, nevertheless, some patients progress during the use of non-covalent BTK inhibitors and newer agents, such as pirtobrutinib, have been associated with also improving the outcome in these patients. Interestingly, there are several BTK degraders that have been in development and the initial data is showing that the current study also seems to provide encouraging results in B-cell malignancies. It is also interesting that the results in CNS lymphoma can be an important starting point for future combination strategies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Regeneron: Consultancy; AbbVie: Consultancy; Genmab: Research Funding; BeiGene: Research Funding; ADC Therapeutics: Consultancy, Research Funding; Genentech: Consultancy.
